Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma
Xiao, Zhijie , Wang, Si-Qi, Zhu, Yun , Gao, Xu-Yuan, Tin, Vicky Pui‐Chi, Qin, Jing , Wang, Junwen , Wong, Maria Pik , Xiao, Zhi-Jie , Wang, Jun-Wen, Wong, Maria Pik , Liu, Jing , Gao, Xu-Yuan, Wang, Junwen , Qin, Jing

Mayo Clinic

eLife | July 24, 2017 | Volume: 6 | Issue: No issue available | Pages: No page available

10.7554/elife.26733 | PMID 28737489 Get It

Tumor-initiating cells (TIC) are dynamic cancer cell subsets that display enhanced tumor functions and resilience to treatment but the mechanism of TIC induction or maintenance in lung cancer is not fully understood. In this study, we show the calcium pathway transcription factor NFATc2 is a novel regulator of lung TIC phenotypes, including tumorspheres, cell motility, tumorigenesis, as well as in vitro and in vivo responses to chemotherapy and targeted therapy. In human lung cancers, high NFATc2 expression predicted poor tumor differentiation, adverse recurrence-free and cancer-specific overall survivals. Mechanistic investigations identified NFATc2 response elements in the 3’ enhancer region of SOX2, and NFATc2/SOX2 coupling upregulates ALDH1A1 by binding to its 5’ enhancer. Through this axis, oxidative stress induced by cancer drug treatment is attenuated, leading to increased resistance in a mutation-independent manner. Targeting this axis provides a novel approach for the long-term treatment of lung cancer through TIC elimination.
Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
Du, Meijun , Giridhar, Karthik V. , Tian, Yijun , Tschannen, Michael, Zhu, Jing , Huang, Chiang‐Ching , Kilari, Deepak , Kohli, Manish , Wang, Liang , Giridhar, Karthik V , Kohli, Manish

Mayo Clinic

Oncotarget | July 23, 2017 | Volume: 8 | Issue: 38 | Pages: 63703-63714

10.18632/oncotarget.19476 | PMID 28969022 Get It

Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction
Jin, Xin , Pan, Yunqian , Wang, Liguo , Zhang, Lizhi , Tang, Amy , Billadeau, Daniel D. , Wu, Heshui , Ma, Tao , Huang, Haojie , Wang, Liguo , Tang, Amy H , Jin, Xin

Mayo Clinic

Cancer Research | July 18, 2017 | Volume: 77 | Issue: 16 | Pages: 4328-4341

10.1158/0008-5472.can-16-3143 | PMID 28720574 Get It

Abstract Dysregulation of the MAPK pathway correlates with progression of pancreatic ductal adenocarcinoma (PDAC) progression. IQ motif containing GTPase-activating protein 1 (IQGAP1) is a MAPK scaffold that directly regulates the activation of RAF, MEK, and ERK. Fructose-1,6-bisphosphatase (FBP1), a key enzyme in gluconeogenesis, is transcriptionally downregulated in various cancers, including PDAC. Here, we demonstrate that FBP1 acts as a negative modulator of the IQGAP1–MAPK signaling axis in PDAC cells. FBP1 binding to the WW domain of IQGAP1 impeded IQGAP1-dependent ERK1/2 phosphorylation (pERK1/2) in a manner independent of FBP1 enzymatic activity. Conversely, decreased FBP1 expression induced pERK1/2 levels in PDAC cell lines and correlated with increased pERK1/2 levels in patient specimens. Treatment with gemcitabine caused undesirable activation of ERK1/2 in PDAC cells, but cotreatment with the FBP1-derived small peptide inhibitor FBP1 E4 overcame gemcitabine-induced ERK activation, thereby increasing the anticancer efficacy of gemcitabine in PDAC. These findings identify a primary mechanism of resistance of PDAC to standard therapy and suggest that the FBP1–IQGAP1–ERK1/2 signaling axis can be targeted for effective treatment of PDAC. Cancer Res; 77(16); 4328–41. ©2017 AACR.
Multi‐genic pattern found in rare type of hypopituitarism: a whole‐exome sequencing study of Han Chinese with pituitary stalk interruption syndrome
Guo, Qinghua , Wang, Chengzhi , Qin, Yan , Han, Baiyu, Wang, Anping , Wang, Baoan, Dou, Jingtao , Wu, Xiaosheng , Mu, Yiming , Wang, Cheng-Zhi , Wu, Xiao-Sheng, Wu, Zhiqiang

Mayo Clinic

Journal of Cellular and Molecular Medicine | July 14, 2017 | Volume: 21 | Issue: 12 | Pages: 3626-3632

10.1111/jcmm.13272 | PMID 28707430 Get It

AbstractPituitary stalk interruption syndrome (PSIS) is a rare type of hypopituitarism manifesting various degrees of pituitary hormone deficiency. Although mutations have been identified in some familial cases, the underpinning mechanisms of sporadic patients with PSIS who are in a vast majority remain elusive, necessitating a comprehensive study using systemic approaches. We postulate that other genetic mechanisms may be responsible for the sporadic PSIS. To test this hypothesis, we conducted a study in 24 patients with PSIS of Han Chinese with no family history using whole‐exome sequencing (WES) and bioinformatic analysis. We identified a group of heterozygous mutations in 92% (22 of 24) of the patients, and these genes are mostly associated with Notch, Shh, Wnt signalling pathways. Importantly, 83% (20 of 24) of the patients had more than one mutation in those pathways suggesting synergy of compound mutations underpin the pathogenesis of sporadic PSIS.
Using whole‐exome sequencing to investigate the genetic bases of lysosomal storage diseases of unknown etiology
Wang, Nan , Zhang, Yeting , Gedvilaite, Erika , Loh, Jui Wan , Lin, Timothy, Liu, Xiuping , Liu, Chang‐Gong, Kumar, Dibyendu , Donnelly, Robert, Raymond, Kimiyo , Schuchman, Edward H. , Sleat, David E. , Lobel, Peter , Xing, Jinchuan

Mayo Clinic

Human Mutation | July 13, 2017 | Volume: 38 | Issue: 11 | Pages: 1491-1499

10.1002/humu.23291 | PMID 28703315 Get It

Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.
Javle, Milind , Catenacci, Daniel V.T. , Jain, Apurva , Young, Lauren , Wang, Kai , Chung, Jon , Schrock, Alexa B. , Gay, Laurie M. , Ahn, Daniel H. , Kelley, Robin Kate , Ganesan, Shridar , Stephens, Phil , Miller, Vincent A. , Ali, Siraj M. , Shroff, Rachna T. , Hezel, Aram F. , Goyal, Lipika , Bekaii‐Saab, Tanios , Ross, Jeffrey S

Mayo Clinic

Journal of Clinical Oncology | July 6, 2017 | Volume: 35 | Issue: 15_suppl | Pages: 4076-4076

10.1200/jco.2017.35.15_suppl.4076 Get It

4076 Background: Gallbladder carcinoma (GBC) is commonly diagnosed at an advanced, unresectable disease stage and has a poor prognosis. Comprehensive genomic profiling (CGP) has a developing role in guiding systemic, precision anti-cancer therapy. Methods: We performed hybrid capture-based CGP on FFPE samples for 491 consecutive advanced GBCs. Mean coverage depth was >550X for up to 315 cancer-related genes plus 37 introns from 28 genes frequently rearranged in cancer. All 4 classes of genomic alterations (GA) were detected. Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA. Results: Median age was 64 (range 25-88) and 69% (337/491) of patients were female. 96% (470), 2.9% (14), and 1.4% (7) of GBC patients had the diagnosis of adenocarcinoma, adenosquamous, or carcinoma not specified (NOS), respectively. Commonly altered genes were TP53 (62%), CDNK2A (31%), ARID1A (18%), and SMAD4 (15%), and most of the genetic aberrations (GA) were short variants. Potentially targetable SCNAs (including ERBB genes, MET, FGFRs, and the CCND1-FGF3/4/19 11q13 amplicon) were identified in 21% of cases (Table). Oncogenic BRAF, ALK, or FGFR2/3 rearrangements were found in 7 cases (1.4%). Moreover, 7.8% of cases had BRCA2 or ATM GA, and 0.8% had INI1loss suggesting benefit from PARP or EZH2 inhibitors, respectively. TMB was low; the 25th, 50th, and 75th percentiles were 2.5, 3.8 and 6.3 mutations/Mb, respectively. Less than 1% of cases had microsatellite instability. Radiological response to TKIs and immunotherapy was noted. Conclusions: In addition to the significant opportunity for anti-HER targeted therapies, other subsets of GBC cases harbored kinase GA (particularly SCNA), the 11q13 amplicon, or BRCA2/ ATM/ INI1mutations that are linked to therapeutic benefit. How the frequency of both driver SCNA and DNA repair alterations in GBC can be linked with inflammation awaits additional investigation. [Table: see text]
Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium
Barrdahl, Myrto , Hopper, John L. , Southey, Melissa C. , Fasching, Peter A. , Beckmann, Matthias W. , Gago-Domínguez, Manuela , Castelao, Jose E. , Guénel, Pascal , Truong, Thérèse , Bojesen, Stig E. , Gapstur, Susan M. , Gaudet, Mia M. , Brenner, Hermann , Brauch, Hiltrud , Hamann, Ute , Mannermaa, Arto, Lambrechts, Diether , Jongen, Lynn , Flesch‐Janys, Dieter, Thoene, Kathrin, Couch, Fergus J. , Simard, Jacques , Goldberg, Mark S. , Figueroa, Jonine D. , Michailidou, Kyriaki , Bolla, Manjeet K. , Wang, Qin , Eilber, Ursula, Swerdlow, Anthony J. , Schoemaker, Minouk J. , García‐Closas, Montserrat , Easton, Douglas F. , Chang‐Claude, Jenny , Durocher, Francine , Barrdahl, Myrto , Lambrechts, Diether , Rudolph, Anja , Fasching, Peter A , Barrdahl, Myrto , Rudolph, Anja , Broeks, Annegien , Arndt, Volker , Mannermaa, Arto, Couch, Fergus J. , Giles, Graham G. , Dennis, Joe , Behrens, Sabine , Czene, Kamila , Hall, Per N , Cox, Angela , Cross, Simon S. , Dunning, Alison M. , Kaaks, Rudolf , Pharoah, Paul D.P. , Schmidt, Marjanka K. , Milne, Roger L. , Lambrechts, Diether , Swerdlow, Anthony J , Southey, Melissa C , Lambrechts, Diether , Brenner, Hermann , Gago-Dominguez, Manuela , Guénel, Pascal , García-Closas, Montserrat , Michailidou, Kyriaki , Simard, Jacques , Figueroa, Jonine D , Bojesen, Stig E , Schoemaker, Minouk J , Truong, Therese , Brauch, Hiltrud

Mayo Clinic

International Journal of Cancer | July 3, 2017 | Volume: 141 | Issue: 9 | Pages: 1830-1840

10.1002/ijc.30859 | PMID 28670784 Get It

Investigating the most likely causal variants identified by fine‐mapping analyses may improve the power to detect gene–environment interactions. We assessed the interplay between 70 single nucleotide polymorphisms identified by genetic fine‐scale mapping of susceptibility loci and 11 epidemiological breast cancer risk factors in relation to breast cancer. Analyses were conducted on up to 58,573 subjects (26,968 cases and 31,605 controls) from the Breast Cancer Association Consortium, in one of the largest studies of its kind. Analyses were carried out separately for estrogen receptor (ER) positive (ER+) and ER negative (ER–) disease. The Bayesian False Discovery Probability (BFDP) was computed to assess the noteworthiness of the results. Four potential gene–environment interactions were identified as noteworthy (BFDP < 0.80) when assuming a true prior interaction probability of 0.01. The strongest interaction result in relation to overall breast cancer risk was found between CFLAR‐rs7558475 and current smoking (ORint = 0.77, 95% CI: 0.67–0.88, pint = 1.8 × 10−4). The interaction with the strongest statistical evidence was found between 5q14‐rs7707921 and alcohol consumption (ORint =1.36, 95% CI: 1.16–1.59, pint = 1.9 × 10−5) in relation to ER– disease risk. The remaining two gene–environment interactions were also identified in relation to ER– breast cancer risk and were found between 3p21‐rs6796502 and age at menarche (ORint = 1.26, 95% CI: 1.12–1.43, pint =1.8 × 10−4) and between 8q23‐rs13267382 and age at first full‐term pregnancy (ORint = 0.89, 95% CI: 0.83–0.95, pint = 5.2 × 10−4). While these results do not suggest any strong gene–environment interactions, our results may still be useful to inform experimental studies. These may in turn, shed light on the potential interactions observed.
Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer
Espíndola‐Netto, Jair Machado , Chini, Claudia C.S. , Tarragó, Mariana G., Wang, Enfeng , Dutta, Shamit K., Pal, Krishnendu , Sola‐Penna, Mauro , Chini, Eduardo N. , Tarragó, Mariana, Dutta, Shamit, Mukhopadhyay, Debabrata , Pal, Krishnendu

Mayo Clinic

Oncotarget | June 29, 2017 | Volume: 8 | Issue: 49 | Pages: 85054-85067

10.18632/oncotarget.18841 | PMID 29156703 Get It

Body mass index and breast cancer survival: a Mendelian randomization analysis
Guo, Qi , Burgess, Stephen , Bolla, Manjeet K. , Wang, Qin , Abraham, Jean , Aittomäki, Kristiina, Andrulis, Irene L. , Apicella, Carmel, Berg, Christine D. , Blomqvist, Carl , Bojesen, Stig E. , Brand, Judith S. , Brenner, Hermann , Burwinkel, Barbara , Caldas, Carlos , Campa, Daniele , Canzian, Federico , Chang‐Claude, Jenny , Couch, Fergus J. , Darabi, Hatef, Diver, W. Ryan , Earl, Helena , Eccles, Diana M, Ekici, Arif B. , Eriksson, Mikael , Evans, D. Gareth , Fasching, Peter A. , Figueroa, Jonine D. , Flesch‐Janys, Dieter, Flyger, Henrik, Gapstur, Susan M. , Gaudet, Mia M. , Glendon, Gord, Grip, Mervi, Haeberle, Lothar, Haiman, Christopher A., Hamann, Ute, Hankinson, Susan E. , Hein, Alexander , Hiller, Louise , Hogervorst, Frans B.L., Holleczek, Bernd , Hooning, Maartje J. , Hoover, Robert N. , Humphreys, Keith , Hunter, David J., Hüsing, Anika , Jakubowska, Anna , Jukkola‐Vuorinen, Arja , Kabisch, Maria, Investigators, kConFab/AOCS, Knight, Julia A. , Koppert, Linetta B. , Kosma, Veli‐Matti , Kristensen, Vessela N. , Lambrechts, Diether , Li, Jingmei , Lindblom, Annika , Lindström, Sara, Lissowska, Jolanta , Lubiński, Jan , Machiela, Mitchell J. , Mannermaa, Arto, Manoukian, Siranoush , Margolin, Sara , Marmé, F., McLean, Catriona , Menéndez, Primitiva, Mulligan, Anna Marie , Muranen, Taru , Neven, Patrick , Nielsen, Sune F. , Nordestgaard, Børge G. , Perez, Jose IA, Peterlongo, Paolo , Phillips, Kelly‐Anne , Poole, Christopher, Pylkäs, Katri , Radice, Paolo , Rüdiger, Thomas , Sawyer, Elinor J. , Schumacher, Fredrick R. , Seynaeve, Caroline, Shah, Mitul , Smeets, Ann , Southey, Melissa C. , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Ulmer, Hans-Ulrich, Vachon, Celine M. , Ouweland, Ans MW van den, Veer, Laura J. van’t , Wildiers, Hans , Winqvist, Robert , Zamora, M. Pilar , Chenevix‐Trench, Georgia , Dörk, Thilo , Easton, Douglas F. , García‐Closas, Montserrat , Kraft, Peter , Hopper, John L. , Pharoah, Paul D.P., Eccles, Diana , Bowtell, David D.L. , Lambrechts, Diether , Vachon, Celine, Turman, Constance , Lush, Michael J. , Arndt, Volker , Benı́tez, Javier , Bonanni, Bernardo , Broeks, Annegien , Chanock, Stephen Jacob , Chin, Suet‐Feung , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Cybulski, Cezary , Czene, Kamila , Devilee, Peter , Dunning, Alison M. , Eriksson, Mikael , Giles, Graham G. , Gronwald, Jacek , Hall, Per N , Hankinson, Susan E. , Hartikainen, Jaana M. , Hooning, Maartje J. , Kaaks, Rudolf , Kataja, Vesa , Investigators, kConFab/AOCS, Marchand, Loı̈c Le , Mannermaa, Arto, Martens, John W.M. , Milne, Roger L. , Nevanlinna, Heli , Olson, Janet E. , Rahman, Nazneen , Rudolph, Anja , Seibold, Petra , Tsimiklis, Helen , Vachon, Celine M. , Willett, Walter C. , Zheng, Wei , Schmidt, Marjanka K. , Dörk, Thilo , Lambrechts, Diether , Peterlongo, Paolo , Hein, Alexander , Eccles, Diana , Radice, Paolo , Lissowska, Jolanta , Caldas, Carlos , Evans, D Gareth , Southey, Melissa C , Canzian, Federico , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Li, Jingmei , Muranen, Taru A , García-Closas, Montserrat , Ekici, Arif B , Kraft, Peter , Chenevix-Trench, Georgia , Figueroa, Jonine D , Machiela, Mitchell J , Hüsing, Anika , Bowtell, David D , Pylkäs, Katri , Manoukian, Siranoush , Lubinski, Jan , Bojesen, Stig E , Phillips, Kelly-Anne , Wildiers, Hans , Mclean, Catriona , Lindblom, Annika , Sawyer, Elinor J

Mayo Clinic

International Journal of Epidemiology | June 29, 2017 | Volume: 46 | Issue: 6 | Pages: 1814-1822

10.1093/ije/dyx131 | PMID 29232439 Get It

Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study
Hein, Alexander , Rack, Brigitte , Li, L. , Ekici, Arif B. , Reis, André , Lux, Michael P. , Cunningham, Julie M. , Rübner, Matthias, Schneeweiß, Andreas , Tesch, Hans , Lichtenegger, W., Fehm, Tanja , Heinrich, G. , Rezai, Mahdi , Beckmann, MW, Janni, Wolfgang , Weinshilboum, Richard, Wang, L. , Fasching, PA, Häberle, Lothar , Fridley, Brooke L. , Hein, Alexander , Lux, Michael P , Ekici, Arif B , Reis, André , Fehm, Tanja

Mayo Clinic

Geburtshilfe und Frauenheilkunde | June 28, 2017 | Volume: 77 | Issue: 06 | Pages: 651-659

10.1055/s-0042-113189 | PMID 28757652 Get It

AbstractLarge-scale genotyping studies have identified over 70 single nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk. However, knowledge regarding genetic risk factors associated with the prognosis is limited. The aim of this study was therefore to investigate the prognostic effect of nine known breast cancer risk SNPs. BC patients (n = 1687) randomly sampled in an adjuvant, randomized phase III trial (SUCCESS A study) were genotyped for nine BC risk SNPs: rs17468277(CASP8), rs2981582(FGFR2), rs13281615(8q24), rs3817198(LSP1), rs889312(MAP3K1), rs3803662(TOX3), rs13387042(2q35), rs4973768(SLC4A7), rs6504950(COX11). Cox proportional hazards models were used to test the SNPsʼ association with overall survival (OS) and progression-free survival (PFS). Additional analyses were carried out for molecular subgroups. rs3817198 in LSP1 (lymphocyte-specific protein 1) was the only SNP that significantly influenced OS (p = 0.01) and PFS (p < 0.01) in the likelihood ratio test comparing the genetic survival model with the clinical survival model. In the molecular subgroups, triple-negative patients with two minor alleles in rs3817198 had a much better prognosis relative to OS (adjusted HR 0.03; 95% CI 0.002 – 0.279) and PFS (HR 0.09; 95% CI 0.02 – 0.36) than patients with the common alleles. The same effect on PFS was shown for patients with luminal A tumors (HR 0.19; 95% CI 0.05 – 0.84), whereas patients with luminal B tumors had a poorer PFS with two minor alleles (HR 2.13; 95% CI 1.02 – 4.40). The variant in rs3817198 has a prognostic effect particularly in the subgroup of patients with triple-negative BC, suggesting a possible link with immunomodulation and BC.